Top Sunnyvale, CA Biotech Companies (8)
Inflammatix is developing an innovative point-of-care instrument platform to be used with a test to aid in the diagnosis of acute infection and sepsis by harnessing the immune system to deliver advanced immune response diagnostics. Our test rapidly informs the clinician about the likelihood of bacterial or viral infection and the need for ICU level care in the emergency department. Faster results may translate into more timely and appropriate therapy and level of care decisions. *Products in development, are not for sale, and do not have marketing approval or clearance from regulatory authorities in any jurisdiction.
Orthofix Medical Inc. began in a small farmhouse in Verona Italy in 1980 when orthopedic researcher Giovanni De Bastiani recognized the bone’s natural repair capability, a concept he called “dynamization.” With that in mind, he created the first external fixation device. Today, Orthofix has grown to more than 1,200 employees with locations in the U.S., Italy, Germany, France, the U.K., Brazil, and Australia. Our products help patients in more than 70 countries around the world. The Company’s mission is to deliver innovative, quality-driven solutions as we partner with health care professionals to improve patient mobility. Headquartered in Lewisville, Texas, the company has two strategic business units: Spine and Orthopedics. Orthofix products are widely distributed via the company's sales representatives and distributors. In addition, Orthofix is collaborating on research and development activities with leading clinical organizations such as MTF Biologics, the Orthopedic Research and Education Foundation, and the Texas Scottish Rite Hospital for Children. Orthofix makes a difference in the lives of others by providing our surgeon customers with innovative medical devices to meet the needs of their patients. Every day we are optimizing our operations, improving efficiencies, and examining our systems to provide the best support possible to our representatives, surgeons and patients.
At Elekta, our outcome-driven and cost-efficient solutions provide lasting clinical difference and are developed through sustainable environmental, social and governance practices. We’ve been working openly and proactively with clinicians and our partners for almost half a century to advance precision radiation therapy and meet continuously evolving patient needs—no matter where they are in the world. To us, it's personal, and our global team of 4,700 employees combine passion, science, and imagination to profoundly change cancer care. We don’t just build technology, we build hope. Elekta is headquartered in Stockholm, Sweden, with offices in 120 countries and listed on Nasdaq Stockholm.
NovoNutrients is a fundamentally new way to make the building blocks of food, using natural microbes to break down molecules and reassemble them into lowest-cost feed and food ingredients. The process's key inputs are hydrogen and carbon dioxide. Those untreated, waste emissions of CO2 can come from industrial production of cement, ethanol, pulp, paper, fuels, or many other products. Gasification, SMR, and electrolysis (of water) all produce hydrogen. The latter means our tech will be a conduit from generating clean power to storing food energy. Advantaged in cost, quality, and sustainability, we’ll initially disrupt the aquaculture portions of two large feed ingredient markets: additives and “fishmeal”, the protein feed ingredient made from fish (soon $40B and $12B, respectively). Our initial market focus is protein for seafood farming, but the company is also starting to put similar resources into developing products to accelerate a global transition away from all conventional meat and fish. [Oakbio, Inc. doing business as NovoNutrients]
Element Biosciences is a multi-disciplinary startup focused on innovating genetic analysis tools for the research and diagnostic markets. We are developing a modular and high-performing DNA sequencing platform that will deliver high-quality data, increase workflow flexibility, and make next-generation sequencing technology more accessible. Our proprietary approach to improving the signal-to-noise ratio allows us to provide groundbreaking innovations in surface chemistry, instrumentation, and biochemistry to drastically decrease run costs and capital costs while delivering high sequencing data quality.
Cepheid is dedicated to improving healthcare by pioneering molecular diagnostics that combine speed, accuracy, and flexibility. The company's GeneXpert® systems and Xpert® tests automate highly complex and time-consuming manual procedures, providing A Better Way for institutions of any size to perform world-class PCR testing. Cepheid’s broad test portfolio spans respiratory infections, blood virology, women’s and sexual health, TB and emerging infectious diseases, healthcare-associated infectious diseases, oncology and human genetics. The company’s solutions deliver actionable results where they are needed most – from central laboratories and hospitals to near-patient settings. For more information, visit http://www.cepheid.com.
23andMe, headquartered in Sunnyvale, CA, is a leading consumer genetics and research company. Founded in 2006, the company’s mission is to help people access, understand, and benefit from the human genome. 23andMe has pioneered direct access to genetic information as the only company with multiple FDA authorizations for genetic health risk reports. The company has created the world’s largest crowdsourced platform for genetic research, with 80 percent of its customers electing to participate. The 23andMe research platform has generated more than 180 publications on the genetic underpinnings of a wide range of diseases, conditions, and traits. The platform also powers the 23andMe Therapeutics group, currently pursuing drug discovery programs rooted in human genetics across a spectrum of disease areas, including oncology, respiratory, and cardiovascular diseases, in addition to other therapeutic areas. 23andMe was named as one of the San Francisco Chronicle's Top Workplaces and one of Comparably's Best Places to Work in 2022. CEO, Anne Wojcicki was also named one of Glassdoor’s top CEOs in 2019 and one of Comparably’s "Best CEOs for Women" in 2021 and 2022. More information is available at www.23andMe.com.
Rubedo Life Sciences is a biopharmaceutical company developing a broad portfolio of innovative therapies engineered to target cells which drive chronic age-related diseases. Our proprietary ALEMBIC™ drug discovery platform has engineered novel first-in-class small molecules designed to selectively target senescent cells, which play a key role in the progression of pulmonary, dermatological, oncological, neurodegenerative, fibrotic and other chronic disorders. The Rubedo leadership team is composed of industry leaders and pioneers in chemistry, technology, and the life sciences, with a deep bench of expertise in drug development and commercialization spanning from large pharma to biotech innovators. The company is based in Sunnyvale, CA.
